# Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

> **NCT02987244** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 100 (estimated)

## Conditions studied

- T Cell Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Chidamide
- **DRUG:** Cyclophosphamide
- **DRUG:** Epirubicin
- **DRUG:** Vindesine
- **DRUG:** Etoposide
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT02987244
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03
- **Primary completion:** 2020-03
- **Final completion:** 2023-03
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2016-12-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02987244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02987244, "Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02987244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*